Cost-utility analysis of rimonabant in the treatment of obesity.

  title={Cost-utility analysis of rimonabant in the treatment of obesity.},
  author={Christian Hampp and Abraham G. Hartzema and Teresa L. Kauf},
  journal={Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research},
  volume={11 3},
OBJECTIVE To estimate the incremental cost-utility ratio (ICUR) of rimonabant 20 mg/day in the treatment of obesity from a third-party payer's perspective. METHODS Pooled data from three randomized clinical trials were used to develop a decision tree with five treatment alternatives: 1- and 2-year treatment with rimonabant, 2-year placebo, 1-year rimonabant followed by 1-year placebo, and no treatment. All alternatives, except no treatment, were accompanied by lifestyle interventions… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 12 extracted citations


Publications referenced by this paper.
Showing 1-10 of 50 references

Are bariatric surgical

  • L Salem, CC Jensen, DR. Flum
  • Int J Obes 2007;31:189–96
  • 2007

The relationship between body mass index and health - related quality of life : comparing the EQ5 D , EuroQol VAS and SF6 D

  • TH Sach, GR Barton, M Doherty
  • Int J Obes
  • 2007

Drug treatments

  • RS Padwal, Majumdar
  • 2005

Similar Papers

Loading similar papers…